Johnson & Johnson $JNJ Stock Holdings Reduced by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board has reduced its holdings in Johnson & Johnson by 38.6%, selling nearly 1.75 million shares, bringing its total ownership to approximately 2.78 million shares valued at $460.87 million.
• Johnson & Johnson recently reported earnings of $2.77 per share, exceeding analysts' expectations of $2.68, and revealed quarterly revenue of $23.74 billion, up 5.8% compared to the previous year.
• The company declared a quarterly dividend of $1.30, equivalent to an annual yield of 3.0%, with a payout ratio of 55.61% for shareholders of record by August 26th.

Canada Pension Plan Investment Board cut its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 38.6% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,779,012 shares of the company's stock after selling 1,748,998 shares during the period. Canada Pension Plan Investment Board owned 0.12% of Johnson & Johnson worth $460,871,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in JNJ. Lantz Financial LLC increased its stake in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company's stock worth $1,986,000 after purchasing an additional 377 shares during the last quarter. Sulzberger Capital Advisors Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth $453,000. Apexium Financial LP raised its holdings in Johnson & Johnson by 10.7% during the first quarter. Apexium Financial LP now owns 23,989 shares of the company's stock valued at $3,978,000 after buying an additional 2,310 shares in the last quarter. Joel Isaacson & Co. LLC raised its holdings in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company's stock valued at $12,294,000 after buying an additional 2,526 shares in the last quarter. Finally, State of Wyoming lifted its position in shares of Johnson & Johnson by 205,580.0% in the fourth quarter. State of Wyoming now owns 10,284 shares of the company's stock worth $1,487,000 after buying an additional 10,279 shares during the last quarter. Institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.7%

NYSE JNJ opened at $175.50 on Friday. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $181.16. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock's 50 day moving average is $165.45 and its two-hundred day moving average is $159.86. The company has a market capitalization of $422.67 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 2.25 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the prior year, the business posted $2.82 earnings per share. The business's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 3.0%. Johnson & Johnson's payout ratio is currently 55.61%.

Wall Street Analyst Weigh In

JNJ has been the topic of a number of analyst reports. Bank of America increased their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. Citigroup increased their price target on Johnson & Johnson from $185.00 to $200.00 and gave the company a "buy" rating in a report on Thursday, August 21st. Royal Bank Of Canada boosted their price objective on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a report on Thursday, July 17th. Finally, UBS Group boosted their target price on shares of Johnson & Johnson from $180.00 to $190.00 and gave the stock a "buy" rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.